The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. The coronary Drug Project Research Group

JAMA. 1973 Nov 5;226(6):652-7.
No abstract available

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Anticholesteremic Agents / therapeutic use
  • Clinical Trials as Topic
  • Clofibrate / therapeutic use
  • Coronary Disease / drug therapy*
  • Coronary Disease / prevention & control
  • Dextrothyroxine / therapeutic use
  • Drug Evaluation*
  • Drug Therapy, Combination
  • Estrogens, Conjugated (USP) / administration & dosage
  • Estrogens, Conjugated (USP) / adverse effects*
  • Estrogens, Conjugated (USP) / therapeutic use
  • Follow-Up Studies
  • Humans
  • Lipoproteins, LDL / blood*
  • Lipoproteins, VLDL / blood*
  • Male
  • Middle Aged
  • Myocardial Infarction / diagnosis
  • Nicotinic Acids / therapeutic use
  • Placebos
  • Recurrence
  • Sodium
  • Time Factors

Substances

  • Anticholesteremic Agents
  • Estrogens, Conjugated (USP)
  • Lipoproteins, LDL
  • Lipoproteins, VLDL
  • Nicotinic Acids
  • Placebos
  • Dextrothyroxine
  • Sodium
  • Clofibrate